Orbis Medicines
A biotechnology company focused on the discovery and development of oral macrocycle drug candidates.
Orbis Medicines has raised €90M across 1 funding round from 6 investors, most recently a Series A round in Jan 2025. Based in Copenhagen, Denmark; active in Healthtech. Data as of 28 Oct 2026.
Copenhagen, Denmarkwww.orbismedicines.com ↗
Total raised
€90M
€90,000,000
Funding rounds
1
Investors
6
distinct backers
Active since
2025-01
latest 2025-01
Funding by year
EUR raised per yearOrbis Medicines — funding by year — interactive chart.
Data table
| Orbis Medicines — funding by year | |
|---|---|
| 2025 | €90M |
Signals
High confidenceRaise-next likelihood59
base rate 44% for Series A
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-07 | Series A | €90M | Cormorant,Eli Lilly,Forbion,NEA (New Enterprise Associates),Novo Holdings,Export and Investment Fund of Denmark (EIFO) | View deal → |
Investors
6Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Oura Health€779MFinland · Healthtech
Global coverage: FundingData